Nasvax
NasVax develops improved vaccines and immunotherapeutic products. The company has four distinct product areas: i. oral anti-CD3 monoclonal antibody immunotherapeutic; ii. VaxiSome® technology, which is an adjuvant-delivery system for enhancing the immunogenicity of vaccines and immunotherapeutics; group-common pneumococcal vaccine, which is a protein-based vaccine that could become the field’s third-generation product; and iv. BBS1-based immunotherapeutics for Alzheimer’s disease.
7-day free trial · no credit card
Verified contacts
3
available on Kipplo
LinkedIn employees
11 to 50
headcount range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 3 verified contacts at Nasvax
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
3 contacts with verified email or phone · masked until revealed.
Showing 1 of 3 verified contacts
Top roles at Nasvax
3 distinct titles indexed · top 3 shown.
- 1ceo
- 1cfo
- 1researcher
Sign up to unlock all 3 contacts at Nasvax
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 3 verified contacts at Nasvax
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.